300347 泰格医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.8771.9439.97210.64316.787
总资产报酬率 ROA (%)3.5521.3897.0897.84013.292
投入资产回报率 ROIC (%)4.1891.6278.2779.11015.264

边际利润分析
销售毛利率 (%)29.16133.95438.57739.63743.553
营业利润率 (%)24.45410.06233.68036.44670.911
息税前利润/营业总收入 (%)25.84510.63932.23534.25766.523
净利润/营业总收入 (%)21.7216.78229.11632.06265.056

收益指标分析
经营活动净收益/利润总额(%)38.138149.45573.53474.60942.767
价值变动净收益/利润总额(%)62.432-50.42427.76524.70157.746
营业外收支净额/利润总额(%)-0.5090.0060.0640.115-0.337

偿债能力分析
流动比率 (X)2.1621.7202.7412.9784.498
速动比率 (X)2.1471.7122.7352.9724.495
资产负债率 (%)14.16316.06717.61117.36313.209
带息债务/全部投入资本 (%)10.25013.09414.35313.7117.799
股东权益/带息债务 (%)852.979644.373578.707604.9151,136.815
股东权益/负债合计 (%)519.453448.724402.258410.935577.926
利息保障倍数 (X)17.05618.455-21.973-15.350-16.030

营运能力分析
应收账款周转天数 (天)74.86071.43355.78646.66544.885
存货周转天数 (天)2.8782.2851.8101.1910.662